CST4在胃癌人群检测中的临床意义  

Clinical significance of CST4 in the detection of gastric cancer population

作　　者：赵安娜 吴爽 张海平[1] 王盼[1] 王中军[1] 曹永献[1] 潘华政[1] ZHAO Anna;WU Shuang;ZHANG Haiping;WANG Pan;WANG Zhongjun;CAO Yongxian;PAN Huazheng(Department of Laboratory Science,Affiliated Hospital of Qingdao University,Qingdao,Shandong,China,266000;Department of Medical Laboratory,Faculty of Medicine,Qingdao University,Qingdao,Shandong,China,266071;Zibo Central Hospital,Zibo,Shandong,China,255000)

机构地区：[1]青岛大学附属医院检验科,山东青岛266000 [2]淄博市中心医院,山东青岛266071 [3]青岛大学医学部医学检验学系,山东淄博255000

出　　处：《分子诊断与治疗杂志》2023年第4期559-563,共5页Journal of Molecular Diagnostics and Therapy

基　　金：山东省自然科学基金面上项目(ZR2020MH318)。

摘　　要：目的探讨人半胱氨酸蛋白酶抑制剂S(CST4)在胃癌人群检测中的临床意义。方法选取青岛大学附属医院2019年1月至2019年12月入院就诊的104例胃癌患者为胃癌组,44例胃良性病变患者(包括胃息肉和胃炎患者)设为胃良性病变组,另选取在门诊就诊的56名健康体检者为对照组。通过酶联免疫吸附试验比较各实验组的CST4检测水平,分析胃癌组患者CST4与临床病理参数关系以及CST4与癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原242(CA242)、糖类抗原125(CA125)、糖类抗原72-4(CA72-4)检测水平的差异。结果胃癌组中CST4的中位数水平明显高于胃良性病变组和对照组,差异有统计学意义(P<0.05);胃癌组中CST4的检测水平,男性与女性比较,差异无统计学意义(P>0.05);年龄<61岁与≥61岁的患者比较,肿瘤分化程度低与肿瘤分化程度中/高的患者比较,TNM分期为Ⅰ/Ⅱ与TNM分期为Ⅲ/Ⅳ的患者比较,差异均有统计学意义(P<0.05)。CST4的阳性检测率明显高于CEA、CA19-9、CA242、CA125、CA72-4单项检测和联合检测,CST4与上述相关肿瘤标志物联合检测阳性率最高,差异有统计学意义(P<0.05)。CST4分别与CEA、CA19-9、CA242、CA125、CA72-4比较,差异有统计学意义(P<0.05)。CST4、CA125+CA19-9+CA242+CA72-4+CEA、CST4+CA125+CA19-9+CA242+CA72-4+CEA三组比较,差异有统计学意义(P<0.05)。CST4诊断胃癌最优的阈值浓度为104.02U/mL,对应的灵敏度和特异度分别为0.529和0.733。结论血清CST4对青岛地区胃癌患者早期诊断具有较好的预测作用;血清CST4可作为胃癌潜在的肿瘤标志物,CST4联合CEA、CA19-9、CA242、CA125、CA72-4对胃癌的血清学诊断效果更高,具有较高的临床价值。Objective To investigate the clinical significance of human cysteine proteinase inhibitor S(CST4)in the detection of gastric cancer population.Methods A total of 104 patients with gastric cancer who were admitted to Qingdao University Hospital from January 2019 to December 2019 were selected as the gastric cancer group,44 patients with benign gastric lesions(including patients with gastric polyps and gastritis)were set as the benign gastric lesion group,and 56 healthy physical examination patients attending outpatient clinics were selected as the control group.The levels of CST4 in the experimental groups were measured by enzyme-linked immunosorbent assay,and the relationship between CST4 and clinicopathological parameters and the levels of CST4 and carcinoembryonic antigen(CEA),glycoantigen 19-9(CA19-9),glycoantigen 242(CA242),glycoantigen 125(CA125),and glycoantigen 72-4(CA72-4)in the gastric cancer group were analyzed.Results The median level of CST4 in the gastric cancer group was significantly higher than that in the benign gastric lesion group and the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the detection level of CST4 in the gastric cancer group between males and females(P>0.05).There were statistically significant differences between patients aged<61 years and≥61 years old,patients with low tumor differentiation and medium/high tumor differentiation,and patients with TNM stageⅠ/Ⅱand TNM stageⅢ/Ⅳ(P<0.05).The positive detection rate of CST4 was significantly higher than that of CEA,CA19-9,CA242,CA125,CA72-4 single and combined detection.The positive rate of combined detection of CST4 and the above-mentioned related tumor markers was the highest,and the difference was statistically significant(P<0.05).Comparing CST4 with CEA,CA19-9,CA242,CA125,CA72-4,respectively,the difference was statistically significant(P<0.05).The difference was statistically significant among the CST4,CA125+CA19-9+CA242+CA72-4+CEA,CST4+CA125+CA19-9+CA242+CA7

关 键 词：人半胱氨酸蛋白酶抑制剂 胃癌 诊断价值 

分 类 号：R735.2[医药卫生—肿瘤]